• Genmab's investigational Rina-S significantly improved progression-free survival and overall survival versus chemotherapy in the Phase 3 RAINFOL-02 trial for platinum-resistant ovarian cancer.
• Rina-S reduced the risk of disease progression or death by 71%; the risk of death fell 57% in the intent-to-treat population.
• The intent-to-treat population included 584 patients, regardless of folate receptor alpha expression or prior mirvetuximab treatment.
• The safety profile remained consistent with previous findings, with no new safety signals or unexpected concerns.
• Based on the results, Genmab plans to discuss potential next steps with regulatory authorities worldwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023662606) on October 23, 2026, and is solely responsible for the information contained therein.